Design and optimization various formulations of PEGylated niosomal nanoparticles loaded with phytochemical agents: potential anti-cancer effects against human lung cancer cells
- 1 March 2023
- journal article
- research article
- Published by Springer Nature in Pharmacological Reports
- Vol. 75 (2) , 442-455
Abstract
Background Phytochemicals and their derivatives are good options to improve treatment efficiency in cancer patients. Artemisinin (ART) and metformin (MET) are widely used phytochemicals to treat various types of cancers. However, their application because of their dose-dependent side effects, and poor bioavailability brings several challenges. Niosome is a novel nanocarrier that is the best choice to encapsulate both lipophilic and hydrophilic drugs. In this study, we synthesized and characterized various formulations of PEGylated (polyethylene glycol) niosomal nanoparticles co-loaded with ART-MET and evaluated their anticancer effect on A549 lung cancer cells. Methods Various formulations of PEGylated noisome were prepared by the thin-film hydration method and characterized in size, morphology, release pattern, and physicochemical structure. The cytotoxic effect of the free ART-MET and optimized PEGylated niosomal nanoparticles loaded with ART-MET on A549 cells were evaluated by MTT assay. Furthermore, the Real-time PCR (RT-PCR) technique used to evaluate apoptotic and anti-apoptotic gene expression. Results The size, encapsulation efficiency (EE), and polydispersity index (PDI) of the optimized nanoparticles are 256 nm, 95%, and 0.202, respectively. Additionally, due to the PEGylation hydrophilic character, there is a major consideration of the high impact of PEGylation on reducing niosome size. According to the results of the MTT assay, free ART-MET and ART-MET-loaded niosomal nanoparticles showed dose-dependent toxicity and inhibits the growth of A549 lung cancer cells. Furthermore, the RT-PCR results indicated that ART-MET-loaded niosomal nanoparticles have a higher anti-proliferative effect by inhibiting anti-apoptotic and inducing apoptotic gene expression in A549 lung cancer cells. Conclusions Our study revealed that the simultaneous use of ART and MET in the optimized PEGylated niosomal nanoparticles delivery system could be an appropriate approach to improve the effectiveness of lung cancer treatment. Graphical abstractKeywords
This publication has 69 references indexed in Scilit:
- Downregulation of KLF4 and the Bcl-2/Bax ratio in advanced epithelial ovarian cancerOncology Letters, 2012
- Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: Characterization and interaction with human lung fibroblastsJournal of Controlled Release, 2010
- Formulation andin vitroevaluation of ciprofloxacin containing niosomes for pulmonary deliveryJournal of Microencapsulation, 2010
- Transdermal absorption enhancement through rat skin of gallidermin loaded in niosomesInternational Journal of Pharmaceutics, 2010
- The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cellsCell Cycle, 2009
- The Role of Cavitation in Liposome FormationBiophysical Journal, 2007
- Caffeine-Loaded Niosomes: Characterization and in Vitro Release StudiesDrug Delivery, 2007
- The Effect of Cholesterol in the Liposome Bilayer on the Stabilization of Incorporated RetinolJournal of Liposome Research, 2005
- Non-ionic surfactant based vesicles (niosomes) in drug deliveryInternational Journal of Pharmaceutics, 1998
- Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span 85)International Journal of Pharmaceutics, 1994